Latest News & Features
Americas
Pfizer has launched a lawsuit against Aurobindo Pharma accusing the Indian pharmaceutical company of infringing patents related to an antibiotic used to treat skin infections. 4 July 2014
Americas
Actavis’s newly-acquired subsidiary Forest Laboratories has bought drug development company Furiex Pharmaceuticals for $1.1 billion. 3 July 2014
Americas
The head of IP at a major pharmaceutical company is set to be named as the next director of the US Patent and Trademark Office, reports have claimed. 2 July 2014
Americas
Genentech has entered into an agreement to buy Seragon, a San Diego-based biotech company that specialises in developing treatments that target hormone-driven cancers, for up to $1.7 billion. 2 July 2014
article
Patent counselling specialist Mark Hayman has joined Bingham McCutchen LLP’s Boston office as a partner. 1 July 2014
Americas
New York-headquartered Forest Laboratories has filed suit against Indian company Aurobindo Pharma to protect Namenda, a treatment for moderate to severe Alzheimer’s disease. 30 June 2014
Asia
IP legislation in the United Arab Emirates is among the strongest in the region but the courts have had so few issues to handle that the country’s lawyers and judges may not yet be well equipped to deal with biotech cases. 27 June 2014
Americas
Patent rejections based on 35 USC §101, which relate to patent eligibility, are “incredibly case-specific”, making it difficult to identify trends or draw broad conclusions, said Matthew McFarlane, a partner at Robins, Kaplan, Miller & Ciresi LLP at the BIO International Convention yesterday. 26 June 2014
Biotechnology
An increasing trend among scientists to want to put their new ideas into the public domain to be shared for the benefit of all is putting research bodies that rely on partnerships with industry for a substantial proportion of their income at risk, according to Jean Derégnaucourt, executive vice-president for business development at the Institut Pasteur in Paris. 26 June 2014
Biotechnology
In a discussion about the implications of the US Supreme Court’s decisions on patent-eligible matter in Prometheus and Myriad at the BIO International Convention yesterday, entitled Patent eligibility from the trenches, an audience member expressed concern that uncertainty over patenting rules could drive American innovators overseas. 26 June 2014